Back to search results

Chronic Kidney Disease in Children (CKiD) Study

This is an observational study, meaning it watches and collects information about children with chronic kidney disease (CKD) over time, rather than testing a specific treatment. Researchers want to understand what causes kidney function to worsen and how CKD affects other health issues like heart problems, brain function, and growth. The study also aims to see how children with CKD manage their social lives and emotional well-being as they grow into young adults. You could join if you are between 6 months and 22 years old and have chronic kidney disease. The main goal is to track how long it takes for participants to need kidney replacement therapy (like dialysis or a transplant). The current status of the study is unclear.

Study design
This is an observational study planning to enroll 1300 participants. It is not testing any specific intervention.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed annually for up to 5 years to measure the time to kidney replacement therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00327860

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

Recruiting
Not specifiedAges 6–22Observational
Johns Hopkins Bloomberg School of Public Health
~1,300 participants
Updated 2026-04-17 on ClinicalTrials.gov

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to Kidney Replacement Therapy
Measured over Annually up to 5 years

Conditions

Chronic Kidney Disease

Explore related trials

Chronic Kidney Disease

NCT00327860

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Children's Mercy Kansas City

    Kansas City, Missouristudy coordinator listed

    Recruiting

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Susan Furth, MD, PhD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
  • Bradley Warady, MD · PRINCIPAL_INVESTIGATOR · Children's Mercy Kansas City
  • Derek Ng, PhD · PRINCIPAL_INVESTIGATOR · Johns Hopkins Bloomberg School of Public Health
  • Jesse Seegmiller, PhD · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Susan Furth, MD, PhD
[email protected]
215-590-2449
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4
Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
Willingness and ability to provide informed consent and assent
For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.

Exclusion

Solid organ (other than kidney), bone marrow or stem cell transplantation
Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab)
HIV infection with detectable viral load despite current antiretroviral therapy
Current pregnancy or pregnancy within past twelve months
Inability to complete major data collection procedures
Not fluent in English or Spanish
Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves)
Existing moderate to severe congenital structural heart disease
Genetic syndromes involving the central nervous system (e.g., Downs syndrome)
History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)\<40, significant impairment in adaptive function and/or inability to independently execute self-care skills)
For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited

What this trial measures

  • Time to Kidney Replacement TherapyAnnually up to 5 years

    The time to Kidney Replacement Therapy (KRT) is assessed as the date of diagnosis to the date of KRT. The exact KRT date is self-reported by the participant and confirmed by medical record abstraction.